Market Overview

UPDATE: Citigroup Upgrades Biogen Idec to Buy on Strong Fundamentals

Related BIIB
FDA Orders New Label For Biogen Idec's MS Drug
UPDATE: Credit Suisse Reiterates On Biogen Idec On Gilenya PPMS Risk
Don't Panic Over Recent Tech Turmoil (Fox Business)

Citigroup upgraded Biogen Idec (NASDAQ: BIIB) from Neutral to Buy and raised the price target from $160.00 to $187.00.

Citigroup commented, "We are upgrading Biogen to Buy as we simply do not see a better entry point anytime soon. We have been on the sidelines hoping to find material weakness, but alas, the fundamentals are too strong and recent PEG-Avonex positive ph 3 data and Tysabri acq from Elan should lead to sustainable upside relative to expectations. We expect that Biogen will come to dominate the MS market in the same way that Gilead dominates HIV and this should lead to tremendous operating synergy and margin expansion. Along with a deep mid-stage pipeline, Biogen should provide sustainable long-term revs/EPS growth."

Biogen Idec closed at $161.75 on Thursday.

Latest Ratings for BIIB

DateFirmActionFromTo
Nov 2014Credit SuisseMaintainsOutperform
Oct 2014CitigroupMaintainsBuy
Oct 2014BairdUpgradesNeutralOutperform

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Upgrades Analyst Ratings

 

Related Articles (BIIB)

Around the Web, We're Loving...

Get Benzinga's Newsletters